Medical
SNMMI 2023 Annual Meeting
Poster #180
Preclinical application of novel isotopes and combination therapy with the FAP-targeted ligand PNT6555.
Download PosterFRONTIER Clinical Trial in Progress
Abstract #TPS3161
FRONTIER: Phase 1 FAP Theranostic Study
Download Poster25th International Symposium of Radiopharmaceutical Sciences
Poster #P-068
Method development for centralized manufacturing of 177Lu-PSMA-I&T
Download PosterTAT12: 12th International Symposium on Targeted Alpha Theray
Preclinical characterization of a rapidly internalizing next generation PSMA ligand for use with Actinium-225
Download PresentationAACR Annual Meeting 2022
Poster #3554
Preclinical characterization of the novel Fibroblast Activation Protein (FAP) targeting ligand PNT6555 for the imaging and therapy of cancer
Download PosterSNMMI 2022 Annual Meeting
Poster #490
Preclinical characterization of the novel Fibroblast Activation Protein (FAP) targeting ligand PNT6555 for the imaging and therapy of cancer
Download PosterEANM Annual Congress 2022
E-Poster #EP-039
PNT2001 EANM 2022 E-Poster Summary: "Development and characterization of a next-generation 225Ac-PSMA radioligand"
Download SummaryESMO Congress 2022
Poster #1400P
Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC): initial results from SPLASH
Download PosterSNMMI Mid-Winter Annual Meeting 2022
Abstract #MWMA2244
Dosimetry results from the SPLASH trial: Study Evaluating Metastatic Castrate Resistant Prostate Cancer (mCRPC) Treatment Using [Lu-177]-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy After Second-Line Hormonal Treatment
Download Presentation